Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalDecoding 5 Analyst Evaluations For OrthoPediatrics
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on OrthoPediatrics (NASDAQ:KIDS) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $38.4, a high estimate of $50.00, and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.73%.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of OrthoPediatrics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kaila Krum | Truist Securities | Lowers | Hold | $31.00 | $39.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $39.00 | $35.00 |
| David Turkaly | JMP Securities | Lowers | Market Outperform | $50.00 | $60.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $35.00 | $31.00 |
| Mike Matson | Needham | Lowers | Buy | $37.00 | $55.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OrthoPediatrics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for OrthoPediatrics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into OrthoPediatrics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on OrthoPediatrics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into OrthoPediatrics's Background
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
Understanding the Numbers: OrthoPediatrics's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: OrthoPediatrics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 14.37%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: OrthoPediatrics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): OrthoPediatrics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.